Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2010-03-25FDA Approved: PAROXETINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for paroxetine hydrochloride from Apotex Corp., granting approval for an additional generic product.
-
FDA approval · 2010-03-22FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Dr.Reddy's Laboratories Limited)
FDA approved a generic version of fluoxetine hydrochloride (an SSRI) from Dr. Reddy's Laboratories Limited under an Original Application (AN…
-
CLINICAL_TRIALS trial_result · 2010-03-04Clinical Trial Update: Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents [Phase 4]
This is a post-marketing Phase 4 study of fluvoxamine maleate for obsessive-compulsive disorder in children and adolescents, which has been …
-
CLINICAL_TRIALS trial_result · 2010-02-02Clinical Trial Update: Cognitive Characteristics of PTSD Patients With OCD
This clinical trial update summarizes cognitive characteristics observed in patients with comorbid Post-Traumatic Stress Disorder and Obsess…
-
CLINICAL_TRIALS trial_result · 2010-02-02Clinical Trial Update: Examining the Usage of Dopamine Blockers in OCD Patients
This clinical trial examining the use of dopamine blockers in Obsessive Compulsive Disorder has completed; no efficacy or safety results are…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-01-07Clinical Trial Update: Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD [Phase 2]
Phase 2 clinical trial evaluating repetitive transcranial magnetic stimulation as an add-on therapy for treatment-resistant obsessive-compul…
-
CLINICAL_TRIALS trial_result · 2009-12-29Clinical Trial Update: N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD) [Phase 2]
Phase 2 trial evaluating N-methylglycine (sarcosine) for obsessive-compulsive disorder has completed; no efficacy results are provided in th…
-
CLINICAL_TRIALS trial_result · 2009-12-01Clinical Trial Update: Augmentation in Tx-resistant OCD: an Open Label Trial
A completed open-label trial evaluating augmentation strategies for treatment-resistant obsessive-compulsive disorder.
-
FDA approval · 2009-09-28FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for fluoxetine from Teva Pharmaceuticals USA, Inc., updating the approval status of the drug. Th…
-
FDA approval · 2009-09-28FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved the supplemental application for sertraline hydrochloride from Granules Pharmaceuticals Inc., confirming regulatory approval of…
-
FDA approval · 2009-09-28FDA Approved: FLUOXETINE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC)
FDA approved a supplemental application for fluoxetine (generic) filed by Chartwell Governmental & Specialty RX, LLC. The approval confirms …
-
FDA approval · 2009-08-31FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for sertraline hydrochloride from Quallent Pharmaceuticals Health LLC, enabling the generic prod…
-
FDA approval · 2009-08-21FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for generic fluoxetine from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2009-08-07FDA Approved: PAXIL — Supplemental Application (Apotex Corp)
FDA approved a supplemental application from Apotex Corp for Paxil (paroxetine hydrochloride).
-
CLINICAL_TRIALS trial_result · 2009-07-29Clinical Trial Update: A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder [NA]
Clinical trial update noting completion of a study evaluating a medication trial combined with behavior therapy for obsessive-compulsive dis…
-
FDA approval · 2009-04-21FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for sertraline hydrochloride from Granules Pharmaceuticals Inc., indicating approval of a modificati…
-
FDA approval · 2009-04-15FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for fluvoxamine maleate filed by Chartwell RX, LLC.
-
FDA label_change · 2009-03-30FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Fluoxetine from Teva Pharmaceuticals USA, Inc., updating the labeling of the approved product.
-
CLINICAL_TRIALS trial_result · 2009-03-26Clinical Trial Update: Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder
A completed clinical trial evaluating memantine augmentation for severe obsessive-compulsive disorder.
-
FDA approval · 2009-03-19FDA Approved: FLUOXETINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved the original ANDA for fluoxetine from Alembic Pharmaceuticals Limited, enabling a generic version of fluoxetine to be marketed.
-
FDA approval · 2009-03-19FDA Approved: FLUOXETINE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for Fluoxetine by Aurobindo Pharma Limited, enabling a generic Fluoxetine product. The approved indica…
-
CLINICAL_TRIALS trial_result · 2009-03-03Clinical Trial Update: Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder [Phase 4]
Phase 4 clinical trial evaluating the effectiveness and safety of adding atypical antipsychotic agents to ongoing SSRI therapy in patients w…
-
FDA approval · 2009-02-27FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for fluvoxamine maleate (generic) submitted by Chartwell RX, LLC.
-
FDA approval · 2009-02-25FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for sertraline hydrochloride from Aurobindo Pharma Limited, a generic version of the antidepressant …
-
CLINICAL_TRIALS trial_result · 2009-02-16Clinical Trial Update: Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial [Phase 4]
A Phase 4 practical trial comparing group cognitive behavioral therapy to fluoxetine for obsessive-compulsive disorder has completed.